Phaseline

Targets › PRG4

PRG4 (Proteoglycan 4): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.

Plays a role in boundary lubrication within articulating joints. Prevents protein deposition onto cartilage from synovial fluid by controlling adhesion-dependent synovial growth and inhibiting the adhesion of synovial cells to the cartilage surface.; FUNCTION: Isoform F plays a role as a growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages. (UniProt, Q92954)

Open in Phaseline: the race on PRG4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lubris BiorhPRG4
Recombinant human proteoglycan 4 (lubricin)
PRG4Phase 2Sjögren's SyndromeDec 2026
Lubris BiorhPRG4 450 μg/ml
Recombinant human proteoglycan 4 (lubricin analog)
PRG4Phase 2Ocular Graft Versus Host DiseaseMar 2027

Conditions

Ocular Graft Versus Host Disease (1) Sjögren's Syndrome (1)

Modalities

small molecule (2)

Companies

Lubris Bio (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.